Amarendra Pegu, Ph.D.Head, Antibody Research at NIAID/NIH
I have been studying the use of monoclonal antibodies to prevent or treat HIV-1 infection by using the NHP model since the past 10 years. We have shown that some of the most broad and potent anti-HIV-1 antibodies that have been recently identified can be used for prevention and treatment of viral infection using nonhuman primate models of HIV-1 infection. Based on these data, the best monoclonal antibodies have been down selected for testing in clinical trials to evaluate their use in both prevention and treatment of HIV-1 infection. I have also been involved in developing novel bi- and tri-specific antibody-based proteins that can be used to prevent or treat HIV-1 infection. These projects have included extensive collaborations with partners from both academia and industry. Overall, our goal is to develop novel antibody-based therapies that can be used in prophylactic and therapeutic strategies against HIV-1.